Comparing imaging techniques in premanifest Huntington's disease
Longitudinal Imaging of Striatal Synaptic Density and Volume in People With Premanifest Huntington's Disease.
This study is testing whether a new type of brain scan can better spot early changes in the brains of people who carry the gene for Huntington's disease before they show any symptoms.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 35 (estimated) |
| Ages | 20 Years to 75 Years |
| Sex | All |
| Sponsor | Universitaire Ziekenhuizen KU Leuven Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Leuven) |
| Trial ID | NCT06626412 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of SV2A PET imaging compared to volumetric MRI in detecting changes in the striatum of individuals who are premanifest carriers of Huntington's disease (HD). Participants will include late premanifest HD mutation carriers and matched healthy controls, all of whom will undergo clinical assessments and imaging evaluations at the start and after two years. The study focuses on understanding the sensitivity of these imaging techniques to track disease progression before symptoms appear.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 20-75 who are carriers of the Huntington's disease mutation with specific clinical criteria.
Not a fit: Patients with significant neuropsychiatric disorders, major internal medical diseases, or contraindications for MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve early detection and monitoring of Huntington's disease, leading to better management strategies.
How similar studies have performed: Other studies have shown promise in using advanced imaging techniques for tracking neurodegenerative diseases, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 20-75 years inclusive. * Capacity to understand the informed consent form. * HD mutation carriers: * HTT (CAG)n ≥ 40 * HD-ISS \< 2 * CAP100 score \> 70 Exclusion Criteria: * neuropsychiatric diseases (other than HD for HD mutation carriers) * major internal medical diseases * white matter lesion load on FLAIR Fazekas score 2 or higher or other relevant MRI abnormalities * history of alcohol abuse or current alcohol abuse (chronic use of more than 15 units per week) or drug abuse * contraindications for MR * pregnancy * previous participation in other research studies involving ionizing radiation with more than 1 mSv in the previous 12 months.
Where this trial is running
Leuven
- University Hospitals Leuven — Leuven, Belgium (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.